|Bid||6.06 x 1200|
|Ask||6.07 x 3200|
|Day's range||5.94 - 6.33|
|52-week range||5.94 - 24.37|
|Beta (5Y monthly)||3.98|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
With stocks breaking out to new highs, many investors are wondering whether this rally can last through the end of the year. TG Watkins, the Director of Stocks at Simpler Trading, thinks small caps are even breaking out which is a clear sign that this rally has legs. Even more, one particular sector he likes is cannabis, which might be getting ready to finally reverse course as The MORE Act removes the marijuana plant from the federal Controlled Substances Act.
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Despite waning investor optimism in the cannabis space, AdvisorShares CEO Noah Hamman says 2020 could be a big year for the sector.
Following the final release of Opportunity Zone regulations on December 19, investors in cannabis dispensaries stand to benefit, some say.
Let's dive into five strong stocks currently trading for under $20 per share we found with our Zacks Stock Screener that investors might want to buy for 2020...
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Investing.com – Canopy Growth has plunged in recent months to levels that finally make it worth buying, Bank of America said on Wednesday, sending shares of the Canadian cannabis producer sharply higher.